TABLE 3.
Summary of presence of recombinant spores of the B. subtilis tasA sinR lux TasA-mCherry strain in the feces of dogs after the first and second oral applications
| DPAa | Presence of recombinant spores in the indicated dog afterb: |
|||||
|---|---|---|---|---|---|---|
| First oral application |
Second oral application |
|||||
| 4 | 5 | Placebo-treated dog | 4 | 5 | Placebo-treated dog | |
| 1 | − | − | − | − | − | − |
| 2 | + | − | − | + | − | − |
| 3 | − | − | − | − | − | − |
| 4 | − | − | − | − | − | − |
| 5 | − | − | − | − | − | − |
| 6 | − | − | − | − | − | − |
a
DPA, days postapplication.
b
Dogs 4 and 5 were treated with 5 × 1010 CFU spores/dose of the B. subtilis tasA sinR lux TasA-mCherry strain diluted in milk, and the placebo-treated dog was treated with milk only. Anal swab samples samples were then collected and tested. The samples were considered positive (+) when they were resistant to heat treatment (80°C for 20 min) and displayed luminescence after germination, as inspected with an IVIS camera.